Compared to Estimates, Neogen (NEOG) Q1 Earnings: A Look at Key Metrics

Neogen (NEOG) reported $209.19 million in revenue for the quarter ended August 2025, representing a year-over-year decline of 3.6%. EPS of $0.04 for the same period compares to $0.07 a year ago.The reported revenue represents a surprise of +2.96% over the Zacks Consensus Estimate of $203.18 million. With the consensus EPS estimate being $0.05, the EPS surprise was -20%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Neogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenues- Food Safety- Natural Toxins & Allergens: $19.96 million versus $18.68 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -2% change.Revenues- Food Safety- Bacterial & General Sanitation: $41.65 million compared to the $38.7 million average estimate based on two analysts. The reported number represents a change of +4.4% year over year.Revenues- Food Safety- Indicator Testing, Culture Media & Other: $79.09 million versus $76.43 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -3.2% change.Revenues- Animal Safety- Life Sciences: $1.86 million versus the two-analyst average estimate of $1.82 million. The reported number represents a year-over-year change of +7.3%.Revenues- Animal Safety- Animal Care & Other: $7.58 million versus $8.16 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +13.5% change.Revenues- Animal Safety: $57.14 million versus the two-analyst average estimate of $54.65 million. The reported number represents a year-over-year change of -0.8%.Revenues- Food Safety: $152.05 million versus $146.62 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -4.6% change.Revenues- Animal Safety- Genomics Services: $16.57 million versus the two-analyst average estimate of $4.42 million. The reported number represents a year-over-year change of +4.3%.Revenues- Food Safety- Genomics Services: $5.56 million compared to the $13.26 million average estimate based on two analysts. The reported number represents a change of -0.6% year over year.Revenues- Animal Safety- Veterinary Instruments & Disposables: $11.91 million compared to the $13.94 million average estimate based on two analysts. The reported number represents a change of -4.9% year over year.View all Key Company Metrics for Neogen here>>>Shares of Neogen have returned +4.1% over the past month versus the Zacks S&P 500 composite's +4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Quantum Computing Stocks Set To SoarArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Neogen Corporation (NEOG): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks